However, in the span of less than a decade, two additional cytotoxic chemotherapies (irinotecan and oxaliplatin), two inhibitors of EGFR (cetuximab and panitunumab) and one monoclonal antibody against VEGF (bevacizumab) have demonstrated efficacy in randomized phase III trials and are being routinely incorporated into regimens to treat metastatic colorectal cancer. This evidence concerns the gene VEGFA and metastatic colorectal cancer.